US Patent 7649011 Inhibitors of human tumor-expressed CCXCKR2

Patent 7649011 was granted and assigned to ChemoCentryx on January, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

ChemoCentryx

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7649011

Date of Patent

January 19, 2010

Patent Application Number

10743281

Date Filed

December 22, 2003

Patent Primary Examiner

‌

Sabiha Qazi

Patent abstract

Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.